Drug Trial Radar · NCT07197645
Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain
Last checked: Nov 20, 2026Latest source record: May 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
33
Planned (sponsor's estimate)
Start
Oct 21, 2025
Primary completion
Apr 26, 2027
Study completion Jul 5, 2027
Sponsor
- Lead sponsor
- Telix Pharmaceuticals (Innovations) Pty LimitedIndustry
- Sponsor type
- Industry
- First posted
- Sep 29, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label, 2-part early phase study designed to evaluate the safety, pharmacokinetics, radiation dosimetry, and preliminary efficacy of TLX090-Tx in patients with painful bone metastases.
Conditions
- Bone Pain
- Metastatic Bone Tumor
- Bone Metastases in Subjects With Advanced Cancer
Interventions
153Sm-DOTMPDrug
TLX090-Tx will be administered as a single ascending intravenous dose to participants with at least 1 confirmed painful osteoblastic bone tumor that exhibits avid uptake as shown by 99mTcdiphosphonate bone scans undertaken within 60 days of dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence and severity of treatment-emergent adverse events (TEAEs) [Safety and Tolerability]Time frame: Up to 6 weeks post-dose
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Biogenix Molecular, LLC, CIRA Health
Miami, Florida · Recruiting
NovaCure
Miami, Florida · Recruiting
Houston Metro Urology
Houston, Texas · Recruiting
Oncology Consultants
Houston, Texas · Recruiting
Excel Diagnostics and Nuclear Oncology Center
Houston, Texas · Recruiting
University of Texas Medical Branch at Galveston (UTMB)
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.